Analysts Expect Fibrocell Science Inc (FCSC) to Post -$0.41 Earnings Per Share
Wall Street analysts predict that Fibrocell Science Inc (NASDAQ:FCSC) will post ($0.41) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Fibrocell Science’s earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.31). Fibrocell Science posted earnings per share of ($0.36) in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.9%. The business is scheduled to issue its next earnings results on Thursday, November 2nd.
On average, analysts expect that Fibrocell Science will report full-year earnings of ($2.30) per share for the current year, with EPS estimates ranging from ($2.58) to ($2.02). For the next financial year, analysts expect that the business will post earnings of ($1.13) per share, with EPS estimates ranging from ($1.23) to ($1.02). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Fibrocell Science.
Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.31) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%.
FCSC has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $5.70 price target on shares of Fibrocell Science in a research note on Friday, June 9th. Zacks Investment Research raised Fibrocell Science from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Wednesday, July 12th. Canaccord Genuity reissued a “buy” rating and issued a $7.00 price target (up previously from $3.00) on shares of Fibrocell Science in a research note on Monday. Finally, ValuEngine raised Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Thursday, July 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $4.74.
Shares of Fibrocell Science (NASDAQ FCSC) traded up 5.96% during midday trading on Friday, reaching $3.38. The company’s stock had a trading volume of 114,100 shares. Fibrocell Science has a 1-year low of $1.57 and a 1-year high of $4.64. The company’s 50-day moving average price is $2.92 and its 200 day moving average price is $2.60. The firm’s market capitalization is $49.74 million.
A hedge fund recently raised its stake in Fibrocell Science stock. Parametric Portfolio Associates LLC increased its holdings in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 48,259 shares of the company’s stock after purchasing an additional 35,000 shares during the period. Parametric Portfolio Associates LLC owned 0.33% of Fibrocell Science worth $194,000 as of its most recent filing with the SEC. 54.70% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/15/analysts-expect-fibrocell-science-inc-fcsc-to-post-0-41-earnings-per-share.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.